Efficacy and safety of afatinib in Chinese patients with EGFR-mutated metastatic non-small-cell lung cancer (NSCLC) previously responsive to first-generation tyrosine-kinase inhibitors (TKI) and chemotherapy: comparison with historical cohort using erlotinib by Lam, KO et al.
Title
Efficacy and safety of afatinib in Chinese patients with EGFR-
mutated metastatic non-small-cell lung cancer (NSCLC)
previously responsive to first-generation tyrosine-kinase
inhibitors (TKI) and chemotherapy: comparison with historical
cohort using erlotinib
Author(s) Lee, VHF; Leung, DENNIS KC; Choy, TIM SHING; Lam, KO; Lam,PUI MEI; Leung, TO WAI; Kwong, DLW
Citation BMC Cancer, 2016, v. 16, article no. 147
Issued Date 2016
URL http://hdl.handle.net/10722/227212
Rights This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
RESEARCH ARTICLE Open Access
Efficacy and safety of afatinib in Chinese
patients with EGFR-mutated metastatic
non-small-cell lung cancer (NSCLC)
previously responsive to first-generation
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Abstract
Background: Afaitnib has shown anti-tumor activity against metastatic EGFR-mutated NSCLC after prior failure to
first generation EGFR-TKI and chemotherapy. We prospectively evaluated the efficacy and safety of afatinib in Chinese
patients who previously failed first-generation TKI and chemotherapy under a compassionate use program (CUP) and
compared to the erlotinib cohort.
Methods: Patients who suffered from metastatic EGFR-mutated NSCLC previously responsive to first-generation TKI
and chemotherapy received afatinib until progression, loss of clinical benefits or intolerable toxicity. Treatment response,
survival and safety were evaluated and compared to the erlotinib cohort.
Results: Twenty-five and 28 patients received afatinib and erlotinib respectively. More patients in the afatinib
group had worse performance status (ECOG 2) than the erlotinib group (p = 0.008). After a median follow-up of
12.1 months, afatinib demonstrated comparable objective response rate (ORR) (20.0 % vs. 7.1 %, p = 0.17) but significantly
higher disease control rate (DCR) (68.0 % vs. 39.3 %, p= 0.04) compared to erlotinib. Median progression-free survival (PFS)
(4.1 months [95 % CI, 2.7–5.5 months] vs. 3.3 months [95 % CI, 2.2–4.3 months], p = 0.97) and overall survival (OS)
were not different between the two groups (10.3 months [95 % CI, 7.5–13.0 months] vs. 10.8 months [95 % CI,
7.4–14.2 months], p = 0.51). Multivariate analyses revealed that age ≤70 years and time to progression (TTP) ≥18 months
for the 1st TKI therapy were prognostic of PFS (p = 0.006 and p = 0.008 respectively). Afatinib caused less rash (60.0 % vs.
67.9 %, p = 0.04) but more diarrhea (60.0 % vs. 10.7 %, p = 0.002) compared to erlotinib.
Conclusion: Afatinib produced encouraging clinical efficacy as 2nd TKI therapy with manageable safety profiles in our
Chinese patients after failure to another TKI and systemic chemotherapy.
This study was registered at ClinicalTrials.gov (NCT02625168) on 3rd December 2015.
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Background
First-generation epidermal growth factor receptor tyrosine-
kinase inhibitors (EGFR-TKI) including geiftinib and er-
lotinib have been the standard first-line treatment for
metastatic non-small-cell lung cancer (NSCLC) harboring
activating EGFR mutation. Global and regional phase III
randomized-controlled trials demonstrated that the me-
dian progression-free survival (PFS) after gefitinib or
erlotinib ranged from 9 to 13 months with the longest
PFS of 13.1 months seen in OPTIMAL study using erloti-
nib [1–7]. Emergence of T790M mutation is the most
common mechanism of acquired resistance to EGFR-TKI,
accounting for about 50–60 % of patients who developed
disease progression after EGFR TKI [8–10].
Afatinib, regarded as second-generation EGFR-TKI, is
an irreversible ErbB family blocker. It was approved as
first-line treatment for EGFR-mutated advanced NSCLC
in European Union and some other countries in 2013. It
exhibits an inhibitory effect on T790M-mutated NSCLC
in in-vitro studies, apart from the expected inhibition on
exon 19 deletion and L858R point mutation [11, 12].
The LUX-Lung1 study published in 2010 has demon-
strated efficacy with improvement in progression-free
survival (3.3 months) for those who had taken afatinib
50 mg daily compared to those who had placebo, after
previous treatment with gefitinib or erlotinib for at least
12 weeks and at least one line of platinum-based chemo-
therapy [13]. More recently, Khan et al. also revealed
similar efficacy of afatinib in the same clinical setting in
a Named Patient Use (NPU) program conducted in the
United Kingdom [14]. To the best of our knowledge, there
has been so far no randomized-controlled trials comparing
the efficacy of afatinib with gefitinib/erlotinib (collectively
grouped as first-generation EGFR-TKI in the latter text) in
those who had prior failure to first-generation EGFR-
TKI for their metastatic EGFR-mutated NSCLC. For
the current analysis, we prospectively evaluated the
efficacy and safety profiles of afatinib as 3rd or 4th line
treatment after prior failure to systemic chemotherapy
and first-generation EGFR-TKI under a Boehringer
Ingelheim sponsored Compassionate Use Program
(CUP), with comparison of our historical cohort who
received erlotinib after previous failure to systemic
chemotherapy and first-generation EGFR-TKI.
Methods
Study design
This study was approved by the ethics committee of the
University of Hong Kong/Hospital Authority Hong Kong
West Cluster (Reference number UW 13–396). It was
commenced in January 2013 with the last patient re-
cruited in February 2014. All patients gave their written
informed consent before recruitment into this study. We
prospectively evaluated the use of afatinib as 3rd or 4th
line treatment after progression to one line of first-
generation EGFR-TKI therapy and one to two lines of
systemic chemotherapy under this CUP. All patients had
documented EGFR activating mutations before the start
of afatinib. Determination of EGFR mutation analysis of
all patients was described previously [15]. Formalin-fixed
paraffin-embedded tumor biopsies before starting 1st
TKI therapy were retrieved. Briefly, tumor enrichment
was performed by micro-dissection under light micros-
copy. Genomic DNA was extracted using QIAmp DNA
FFPE Tissue kit (Qiagen, Hilden, Germany), followed by
polymerase chain reaction (PCR) amplification of EGFR
exons 18 to 21 using intron-based primers and sequenced
in both forward and reverse directions. The last date of
data capture for statistical analysis was on 31st March
2015. The trial was registered with ClinicalTrials.gov
(NCT02625168).
Study population
Patients who had EGFR-mutated metastatic NSCLC with
prior documented objective response to first-generation
TKI (gefitinib or erlotinib) for 6 months and prior treat-
ment of at least 1 line of systemic chemotherapy were
eligible to join the CUP offered by Boehringer-Ingelheim
Pharma GmbH, Ingelheim, Germany. Patients who had
received anti-vascular endothelial growth factor antagonist
but not anti-EGFR monoclonal antibody in their previous
courses of treatment, either alone or in combination with
systemic chemotherapy were allowed to join this CUP. In
addition, patients who had asymptomatic brain metastases
who had not been on corticosteroids for the treatment of
their brain metastases for at least 14 days prior to afatinib
or erlotinib treatment were also eligible for this study. All
recruited patients had baseline computed tomography
scan of the brain, thorax and abdomen with at least 1
evaluable target lesion defined by Response Evaluation
Criteria for Solid Tumors (RECIST) version 1.1 and
adequate serum hematological, hepatic and renal func-
tion as defined by LUX-Lung1 study [16].
Treatment
The treating physicians then decided the starting dose of
afatinib of either 50 mg, 40 mg or 30 mg once daily
continuously. After commencement of afatinib, they had
regular clinical follow up every 2 weeks for 4 weeks then
every 4 weeks until permanent discontinuation of afati-
nib or death. They also had regular imaging with com-
puted tomography (CT) scan every 8–10 weeks for
tumor response evaluation according to RECIST ver-
sion 1.1 performed by two independent board certified
radiologists blinded to study treatment [16]. Any discrep-
ancies between the two radiologists on tumor response
assessment were resolved by consensus. Treatment inter-
ruption was needed for those who developed grade ≥ 3
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adverse event until it was returned to grade 1 or less. Then
afatinib could be resumed but at a one lower dose level.
Those who received afatinib 30 mg daily as the initial
starting dose would discontinue afatinib permanently if
they developed grade ≥3 events.
Assessment of efficacy and safety profiles
All treatment-related toxicities were collected and graded
according to Common Terminology Criteria for Adverse
Events (CTCAE) version 4.0 [17]. Objective response
(OR) included complete response and partial response
while disease control (DC) included complete response,
partial response and stable disease according to RECIST
1.1. The primary study endpoint was PFS, defined as time
from the date of start of afatinib to the date of objectively
determined progressive disease or death from any cause).
Secondary study endpoints were overall survival (OS, time
from the date of start of afatinib to date of death from any
Table 1 Patient characteristics
Afatinib
(n = 25) (%)
Erlotinib
(n = 28) (%)
p-value
Age (range) 63
(42–85)
59
(36–80)
0.59
Sex (male/female) 11/14 10/18 0.54
ECOG
0 1 (4.0) 0 (0.0) 0.01
1 12 (48.0) 24 (85.7)
2 12 (48.0) 4 (14.3)
0/1 vs. 2 13 (52.0)
vs. 12 (48.0)
24 (85.7)
vs. 4 (14.3)
0.008
Smoking status 0.88
Never smokers 22 (88.0) 25 (89.3)
Current or past smokers 3 (12.0) 3 (10.7)
Histology 0.31
Adenocarcinoma 23 (92.0) 28 (100.0)
Squamous cell carcinoma 1 (4.0) 0 (0.0)
Bronchoalveolar carcinoma 1 (4.0) 0 (0.0)
Initial EGFR mutation
status at diagnosis
0.79
exon 18 mutation 0 1
exon 19 deletion 11 13
exon 19 substitution
mutation
1 1
L858R 8 10
L861Q 0 2
double mutations 1 1
EGFR mutation status with re-biopsy
before afatinib or erlotinib
T790M alone 4 unknown NA
Brain metastasis before
afatinib or erlotinib
6 (24.0) 13 (46.4) 0.09
1st TKI therapy NA
Gefitinib 14 (56.0) 28 (100)
Erlotinib 11 (44.0) 0 (0)
Median duration of
therapy (months, range)
14.5
(3.52–40.64)
9.2
(2.63–24.61)
0.02
Median Time to progression
(months range)
13.9
(0.66–40.15)
9.1
(2.52–24.57)
0.14
Best response 0.42
CR 1 (4.0) 1 (3.6)
PR 23 (92.0) 23 (82.1)
SD 0 (0.0) 3 (10.7)
PD 1 (4.0) 1 (3.6)
Number of lines of prior
chemotherapy before
afatinib or erlotinib
0.08
1 14 (56.0) 22 (78.6)
2 11 (44.0) 6 (21.4)
Table 1 Patient characteristics (Continued)
First-line chemotherapy before
afatinib or erlotinib
25 (100) 28 (100) 0.88
Pemetrexed + cisplatin 3 (12.0) 6 (21.4)
Pemetrexed + carboplatin 9 (36.0) 7 (25.0)
Paclitaxel + carboplatin 4 (16.0) 4 (14.3)
Gemcitabine + carboplatin 5 (20.0) 5 (17.9)
Carboplatin 2 (8.0) 2 (7.1)
Pemetrexed 2 (8.0) 4 (14.3)
Median duration of
therapy (months, range)
3.50
(0.69–17.97)
2.96
(0.66–17.02)
0.85
Median time to progression
(months, range)
3.35
(0.69–17.97)
3.48
(0.85–16.95)
0.76
Second-line chemotherapy before
afatinib or erlotinib
11 (44.0) 6 (21.4) 0.08
Pemetrexed + carboplatin 1 (4.0) 0 (0.0)
Paclitaxel + carboplatin 2 (8.0) 2 (7.1)
Gemcitabine + carboplatin 5 (20.0) 4 (14.3)
Docetaxel 1 (4.0) 0 (0.0)
Vinorelbine 1 (4.0) 0 (0.0)
Pemetrexed 1 (4.0) 0 (0.0)
Median duration of
therapy (months, range)
2.30
(0.66–9.63)
2.92
(0.69–4.34)
0.91
Median time to progression
(months, range)
3.09
(0.66–10.28)
3.25
(0.72–4.44)
0.74
Median time interval between
1st TKI therapy and afatinib
or erlotinib (months, range)
8.38
(2.30–54.28)
6.39
(2.56–20.07)
0.15
Median time interval between
last chemotherapy and afatinib
or erlotinib (months, range)
2.79
(0.46–34.28)
2.58
(0.23–17.05)
0.49
Abbreviations: CR complete response, EGFR epidermal growth factor receptor,
NA not applicable, PD progressive disease, PR partial response, SD stable
disease, TKI tyrosine-kinase inhibitor
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cause), time to progression (TTP) started from the date of
afatinib commencement to the date of objectively deter-
mined progressive disease and safety profiles. All these pa-
rameters of all patients in the afatinib group in this study
were compared to a historical cohort of all patients who
received erlotinib after prior failure to gefitinib and at least
one line of systemic chemotherapy in our department
from January 2009 to December 2011, with the same
inclusion and exclusion criteria as for the patients who
received afatinib in this study. All patients in this erlo-
tinib historical cohort received erlotinib at 150 mg once
daily, and they were assessed by the same imaging mo-
dalities for treatment response evaluation, as well the
same departmental protocol for safety profiles and sur-
vival outcomes as for those who received afatinib in
this study.
Statistical analysis
Mann–Whitney U tests were used for comparison of
non-parametric variables and chi-square tests were per-
formed for baseline and posttreatment discrete variables.
Kaplan-Meier methods with log-rank tests were em-
ployed for comparison of each prespecified survival end-
points and Cox proportional hazard models were used
for prognostic factors for PFS after afatinib or erlotinib
in univariate and multivariate analyses, with afatinib ver-
sus erlotinib, age, sex, performance status, smoking sta-
tus, histology, TTP for 1st TKI therapy, time interval
between 1st TKI and afatinib or erlotinib, TTP for all
lines of prior chemotherapy, time interval between last
chemotherapy and afatinib or erlotinib as covariates. All
statistical analyses were performed by Statistical Pack-
age for Social Sciences (SPSS) version 20 (SPSS, Inc.,
Chicago, IL, USA).
Results
Patient characteristics
The patient characteristics were shown in Table 1. The
median follow-up duration was 12.1 months (range
4.1–28.7 months) for the afatinib group and 12.2 months
(range 0.4–48.7 months) for the erlotinib group. Twenty-
five and 28 patients received afatinib and erlotinib
respectively in this study after initial failure to first-
generation TKI and chemotherapy. Six (24.0 %) and 13
(46.4 %) patients in the afatinib and erlotinib group re-
spectively had asymptomatic brain metastases at baseline.
They all had either gross tumor removal or radiation
therapy for their brain metastases before study com-
mencement. Four patients in the afatinib group had tumor
re-biopsy before commencing afatinib and their recurrent
tumors all harbored T790M mutation in addition to exon
19 deletion. Of them, one had a further L883V mutation on
exon 21 and another patient had small cell transformation.
More patients in the afatinib group had worse Eastern
Cooperative Oncology Group (ECOG) performance status
2 compared to the erlotinib group (p = 0.008). Also the me-
dian duration of 1st TKI therapy was longer in the afatinib
group (14.5 vs. 9.2 months, p = 0.02). Two, 21 and 2 pa-
tients received afatinib 50 mg, 40 mg and 30 mg daily re-
spectively while all patients in the erlotinib group received
erlotinib at 150 mg daily as the starting dose.
Treatment efficacy
ORR for afatinib was 20.0 % while that for erlotinib was
(7.1 %, p = 0.17) (Table 2). DCR was higher with afatinib
(68.0 %) than with erlotinib (39.3 %, p = 0.04). ORR of
brain metastases was similar between the afatinib group
(12.0 %) and the erlotinib group (14.3 %, p = 0.81).
Time to progression and the duration of treatment of
two TKI groups did not differ. Median PFS for the
afatinib group was 4.1 months (95 % confidence inter-
val [CI], 2.7–5.5 months) and 3.3 months (95 % CI,
2.2–4.4 months) for the erlotinib group (p = 0.97)
(Fig. 1a). Median OS was also similar, 10.3 months
(95 % CI, 7.5–13.0 months) for afatinib group and
10.8 months (95 % CI, 7.4–14.2 months) for erlotinib
(p = 0.51) (Fig. 1b). More patients in the afatinib group
received the respective TKI beyond radiological pro-
gression until symptomatic progression (39.1 % vs.
14.8 %, p = 0.05). 2 (8.0 %) patients in the afatinib group
and 1 (5.6 %) patient in the erlotinib group were still
receiving their respective TKI without disease progres-
sion at the time of publication.
Table 2 Treatment outcomes in afatinib and erlotinib arm
Afatinib (%) Erlotinib (%) p-value
Best response 0.09
CR 0 (0.0) 0 (0.0)
PR 5 (20.0) 2 (7.1)
SD 12 (48.0) 9 (32.1)
PD 8 (32.0) 17 (60.7)
Objective response rate 5 (20.0) 2 (7.1) 0.17
Disease control rate 17 (68.0) 11 (39.3) 0.04
Objective response of
brain metastases
3 (12.0) 4 (14.3) 0.81
Median duration of
treatment (months, range)
4.5
(0.2–22.7)
3.3
(0.3–48.7)
0.52
Median time to
progression (months, range)
3.3
(0.2–12.6)
3.3
(0.3–14.4)
0.77
Median PFS (95 % CI)
(months)
4.1 (2.7–5.5) 3.3 (2.2–4.4) 0.97
Median OS (95 % CI)
(months)
10.3
(7.5–13.0)
10.8
(7.4–14.2)
0.51
Abbreviations: CI confidence interval, CR complete response, PD progressive
disease, PFS progression-free survival, PR partial response, SD stable disease,
TKI tyrosine-kinase inhibitor
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In the afatinib group, median PFS was similar be-
tween those with exon 19 deletion (3.9 months [95 %
CI, 2.2–5.7 months]) and L858R mutation (4.1 months
[95 % CI, 1.5–6.7 months], p = 0.94). Insignificant differ-
ence in median PFS was also noted between patients with
exon 19 deletion (3.6 months [93 % CI, 2.3–4.9 months])
and L858R mutation (2.5 months [95 % CI, 1.3–
3.7 months], p = 0.31) in the erlotinib cohort. In addition,
afatinib was not found to produce longer median PFS
(4.2 months [95 % CI, 1.2–7.2 months]) than erlotinib
in patients whose tumors exhibited exon 19 deletion
(3.6 months [95 % CI, 2.2–4.9 months, p = 0.70). Simi-
larly no statistical significance in median OS was noted
between patients who received afatinib (14.2 months
[95 % CI, 6.0–22.3 months]) and who received erlotinib
(18.1 months [95 % CI, 9.7–26.4 months], p = 0.28) for
their tumors which harbored exon 19 deletion. No PFS
or OS advantage with afatinib was also noticed in those
who had L858R mutation in their tumous compared to
those who received erlotinib.
In particular, one of our study patients with previous
gefitinib- and chemotherapy-responsive metastatic bron-
choalveolar carcinoma which harbored exon 19 deletion
had a dramatic and long-lasting response to afatinib for
12.6 months before further disease progression (Fig. 2).
For the 4 patients with documented T790M mutation
before starting afatinib, 1 had partial response (T790M
and exon 19 deletion), 2 had stable disease (one with
T790M, exon 19 deletion and small cell carcinoma and
the other with T790M, exon 19 deletion and L833V
Fig. 1 Kaplan-Meier plots illustrating survival outcomes in patients treated with afatinib or erlotinib as 2nd tyrosine-kinase inhibitor (TKI) therapy after
previous failure to first-generation TKI and chemotherapy. a. Progression-free survival (PFS) in the afatinib and erlotinib group. b. Overall survival (OS) in
the afatinib and erlotinib group. c. PFS comparing those whose time to progression to 1st TKI therapy was ≥18 months versus those whose time to
progression to 1st TKI therapy was <18 months
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mutation) and the remaining 1 patient (T790M, exon 19
deletion and L833V mutation) had his disease pro-
gressed with afatinib. Their TTP ranged from 2.3 to
6.0 months.
Univariate and multivariate analysis of PFS and OS
Univariate analysis revealed that age ≤70 years (Hazard
ratio [HR], 0.50; 95 % CI, 0.25–0.86, p = 0.008) and TTP
to 1st TKI therapy for ≥18 months (HR, 0.38; 95 % CI,
0.18–0.83, p = 0.01) conferred a longer PFS for afatinib
or erlotinib as 2nd TKI therapy (Table 3). They were also
the only prognostic factors for PFS in multivariate ana-
lysis (HR, 0.48; 95 % CI, 0.21–0.74, p = 0.006 and HR,
0.39; 95 % CI, 0.16–0.80,; p = 0.008 respectively). The
median PFS for afatinib or erlotinib in patients whose
TTP to 1st TKI therapy ≥18 months was 5.8 months
(95 % CI, 4.9–6.8 months) as compared to 3.3 months
(95 % CI, 2.5–4.0 months) in patients whose TTP to 1st
TKI therapy <18 months (Fig. 1c). No parameters were
identified as significant prognostic factors for OS.
Post-discontinuation treatment
Seven (28.0 %) and 10 (35.7 %) patients in the afatinib and
erlotinib group respectively received further systemic
chemotherapy after cessation of their respective TKI
therapy, without any statistical significance (p = 0.55).
Similarly, 2 (8.0 %) and 2 (7.1 %) patients in the afatinib
and erlotinib group respectively received another TKI
therapy following discontinuation of their afatinib/erlo-
tinib therapy (p = 0.91). All patients had only 1 line of
post-discontinuation chemotherapy or TKI following
cessation of afatinib/erlotinib, except that 2 patients (1
in afatinib group and 1 in erlotinib group) who re-
ceived 2 lines of post-discontinuation chemotherapy.
The number of lines of post-discontinuation chemo-
therapy and TKI did not differ between the two TKI
groups (p = 0.53 and p = 0.91 respectively).
Toxicity profiles
Treatment-related toxicities differed for afatinib as com-
pared to erlotinib group, as shown in Table 4. Acneiform
rash (both all grades and grade ≥3 events) was more
Fig. 2 Computed tomography images of one of our study patients with metastatic bronchoalveolar carcinoma which harbored exon 19 deletion
treated with afatinib as 2nd TKI therapy after failure to gefitinib and chemotherapy. a. Baseline images showing diffuse ground glass opacities
representing tumor infiltrates in lower lobes of both lungs. b. CT images at 3 months after afatinib showing significant reduction of tumor
infiltrates. c. CT images at 6 months after afatinib showing further response and tumor shrinkage to afatinib
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commonly seen with erlotinib than with afatinib. How-
ever diarrhea was the more frequent and dose-limiting
complication in patients who received afatinib, leading
to hypokalemia in 2 patients. Their diarrhea completely
subsided after temporary afatinib suspension and the
dose of afatinib was subsequently reduced from 40 mg
daily to 30 mg daily. No recurrence of grade 3 diarrhea
occurred following this dose reduction. In addition,
more patients who received afatinib were found to have
impaired liver function. However this was limited to
grade 1 event only with no grade ≥2 events. Treatment
interruption was similar between the afatinib and erloti-
nib group (28.0 % vs. 28.6 % respectively, p = 0.96). Dose
reduction secondary to treatment-related complications
did not differ between the two groups neither (24.0 % vs.
17.9 %, p = 0.58). No patients in either group discontinued
afatinib or erlotinib respectively due to treatment-related
toxicity.
Discussion
Though first-generation EGFR-TKI with gefitinib or
erlotinib has been the standard first-line treatment for
metastatic EGFR-mutated NSCLC as demonstrated in
various phase 3 randomized-controlled clinical trials
[1–7], resistance against these first-generation TKI
eventually develops after a median treatment duration
of 9 to 13 months. It is believed to originate from the
emergence of clones with the ability of generating genetic
alterations which have survival advantages under the se-
lective pressure of the current TKI treatment [18]. The
most common mechanism of acquired resistance is the
presence of T790M mutation on exon 20, accounting for
about 50–60 % of known mutations of acquired TKI re-
sistance [8–10]. When T790M mutation was introduced
in vitro into sequences that contained exon 19 deletion
and L858R mutation, the resultant proteins were found
more resistant to gefitinib in the constructs which con-
tained T790M [9]. Afatinib was found effective in reducing
tumor size in transgenic mice with T790M-L858R muta-
tion and other exon 20 insertion EGFR mutations [11].
Other mechanisms of acquired resistance to TKI include
MET amplification, HER amplification, small cell trans-
formation and rarely secondary mutations for instance
BRAF mutation have been implicated [8, 19–24]. Rebiopsy
of growing tumors after progression to 1st TKI therapy
has caught rising attention recently and enabled us to
comprehend the change in mutation patterns which may
better predict the overall prognosis and guide subsequent
therapy [10, 25]. In our study, 4 of our patients had docu-
mented posttreatment T790M mutation with or without
extra mutations in addition to the pre-existing pretreat-
ment EGFR mutations before commencement of afatinib.
One had partial response, two had stable disease and the
last patient had disease progression after afatinib. This
Table 3 Univariate and multivariate analyses of prognostic
markers for PFS
Univariate analysis
(p-value)
Multivariate analysis
(p-value)
Afatinib vs. erlotinib 0.97 ND
Age ≤70 years 0.008 0.006
Sex 0.79 ND
Smoking status 0.25 ND
Histology 0.62 ND
Performance status 0.66 ND
Time to progression for
1st TKI therapy
0.09 0.06
Time to progression ≥18 months
for 1st TKI therapy
0.01 0.008
Time to progression for all
lines of chemotherapy treatment
before 2nd TKI therapy
0.41 ND
Time interval between end of
1st TKI therapy and start of
afatinib or erlotinib
0.40 ND
Time interval between end of
last chemotherapy treatment
and start of afatinib or erlotinib
0.88 ND
Note: Only covariates found significant in univariate analysis (p < 0.1) were
considered in multivariate analysis
Abbreviations: ND not done, TKI tyrosine-kinase inhibitor
Table 4 Treatment-related toxicity profiles
Afatinib Erlotinib p-value
All grades (%) ≥Grade 3 (%) All grades (%) ≥Grade 3 (%) All grades ≥Grade 3
Rash 15 (60.0) 0 (0.0) 19 (67.9) 5 (17.9) 0.04 0.03
Diarrhea 15 (60.0) 7 (28.0) 3 (10.7) 1 (3.6) 0.002 0.01
Mucositis 1 (4.0) 0 (0.0) 0 (0.0) 0 (0.0) 0.29 NA
Paronychia 2 (8.0) 0 (0.0) 0 (0.0) 0 (0.0) 0.31 NA
Impaired liver function 6 (24.0) 0 (0.0) 1 (3.6) 0 (0.0) 0.02 NA
Hypokalemia 2 (8.0) 2 (8.0) 0 (0.0) 0 (0.0) 0.13 0.13
Abbreviation: NA not applicable
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echoed with previous findings that afatinib exhibited some
antitumor activity against T790M mutation.
Strategies to treat EGFR-mutated NSCLC with acquired
resistance to initial TKI therapy have been continuously
evolving. Rechallenge with gefitinib or erlotinib in previ-
ously TKI-responsive NSCLC upon disease progression
was able to slow down the pace of clinical deterioration
and stabilization of enlargement of some lesions [26, 27].
More recently two Korean studies tested the clinical
efficacy of erlotinib after initial failure to gefitinib and
demonstrated the very modest and limited antitumor
activity, unfortunately the median time to progression was
around 2 months and more than 70 % of patients devel-
oped progressive disease [28, 29]. Another small study also
echoed the short duration of treatment with the dismal
median PFS of 2 months [30].
Afatinib has been studied in patients with prior failure
to first-generation TKI. In the phase II/III LUX-Lung 1
study, significant improvement in median PFS from 1.1
to 3.3 months was revealed as compared to placebo des-
pite a lack of improvement in OS [13]. It was found to
be more potent against T790M compared to first-
generation TKI. The treatment results of our study was
also comparable with that in LUX-Lung1 study (Table 5).
However its efficacy was limited by more potent inhib-
ition against wild-type EGFR and subsequent toxicity
which impairs the delivery of adequate dosing to the tu-
mors [13]. In our study, diarrhea was the leading and
dose-limiting complication which necessitated treatment
interruption and dose reduction. However, acneiform
rash was less common and severe with afatinib com-
pared to erlotinib in our study, which might be a special
feature in Chinese patients (Table 5). Another pan-HER
inhibitor dacomitinib was also investigated in this setting
after prior failure to first-generation TKI in the National
Cancer Institute of Canada BR.26 trial but it failed to
meet its primary survival endpoint, though the outcome
in the EGFR mutant subgroup remains to be reported
[31]. Third-generation TKI specially designed to block
T790M including CO-1686 and AZD9291 have been
evolving and tested currently in phase II/III trials [32, 33].
In 2015, the phase Ib/II studies on CO-1686 and
AZD9291 demonstrated an extremely encouraging ob-
jective response rate of 29 and 21 % respectively in pa-
tients without T790M mutation and 59 and 61 %
respectively in patients with T790M mutation [34, 35].
This has resulted in recent approval of AZD9291 for
the treatment of patients who develop T790M mutation
in their metastatic NSCLC by Food and Drug Adminis-
tration (FDA) of the United States. More interestingly,
they lacked the activity against wild-type EGFR leading
to relatively fewer incidences of rash and diarrhea.
Another approach for maximizing inhibition against ac-
quired resistance is the combination of EGFR-TKI and
anti-EGFR monoclonal antibody, leading to an ORR of
30 % and median PFS of 4.7 months revealed in a phase
Ib/II trial [36, 37].
Though there were no statistical significant differences
in PFS and OS between afatinib and erlotinib, afatinib
was found to have better disease control and borderline
better objective response as compared to erlotinib. Of
much interest, more patients had worse performance
status (ECOG 2) and were treated with 2 previous lines
of chemotherapy in the afatinib group as compared to
those who received erlotinib. They inherently had very
Table 5 Comparison of baseline patient characteristics, treatment
outcomes and selected toxicity profiles after afatinib as 2nd TKI
therapy in LUX-Lung1 and current study
LUX-Lung1 study Current study
Number of patients 390 25
Age (range) 58 (30–85) 63 (42–85)
Male/female (%) 159 (40.8)/231 (59.2) 11 (44.0)/14 (56.0)
ECOG performance
status (%)
0 92 (23.6) 1 (4.0)
1 268 (68.7) 12 (48.0)
2 30 (7.7) 12 (48.0)
Prior EGFR-TKI therapy (%)
Erlotinib 215 (55.1) 14 (56.0)
Gefitinib 152 (39.0) 11 (44.0)
Both 23 (5.9) 0 (0)
Number of lines of prior
chemotherapy (%)
1 231 (59.2) 14 (56)
2 156 (40.0) 11 (44)
3 3 (0.8) 0 (0)
Objective response (%)
Partial response 29 (7.4) 5 (20.0)
Stable disease 198 (50.8) 12 (48.0)
Disease control (%) 227 (58.2) 17 (68.0)
Median progression-free
survival in months (range)
3.3 (2.8–4.4) 4.1 (2.7–5.5)
Median overall survival in
months (range)
10.8 (10.0–12.0) 10.3 (7.5–13.0)
Selected toxicity
profiles (%)
All
grades (%)
≥Grade
3 (%)
All
grades (%)
≥Grade
3 (%)
Rash 305 (78.2) 56 (14.4) 15 (60.0) 0 (0)
Diarrhea 339 (86.9) 66 (16.9) 15 (60.0) 7 (28.0)
Mucositis/stomatitis 237 (60.8) 12 (3.1) 1 (4.0) 0 (0)
Paronychia/nail effect 153 (39.2) 20 (5.1) 2 (8.0) 0 (0)
Hypokalemia 34 (8.7) 11 (2.8) 2 (8.0) 2 (8.0)
Abbreviations: ECOG Eastern Cooperative Oncology Group, EGFR epidermal
growth factor receptor, TKI tyrosine-kinase inhibitor
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limited treatment options because of their borderline
physical fitness and capabilities. In fact 20 (80 %) pa-
tients received afatinib as the last line of treatment
before they succumbed to the disease and more patients
received afatinib beyond disease progression as com-
pared to those in the erlotinib group (p = 0.05). None-
theless, they still enjoyed similar PFS and OS with
afatinib as compared to those with better performance
status who received erlotinib.
We found that age ≤70 years and longer TTP to 1st
TKI therapy ≥18 months were prognostic factors of
longer PFS to 2nd TKI therapy (irrespective of whether
afatinib or erlotinib), in both univariate and multivariate
analyses. Other factors especially the time interval
between 1st TKI and afatinib or erlotinib were not prog-
nostic. This might be contrary to one postulation that
longer interval between 1st and 2nd TKI may promote
re-growth of TKI-sensitive clones leading to continued
response when TKI was rechallenged. However this pos-
tulation has been gradually superseded by the notion of
tumor rebiopsy to delineate the latest mutational status
before initiation of further targeted treatment. We did
not perform tumor rebiopsy before commencement of
afatinib or erlotinib in our study as this was not man-
datory according to LUX-Lung1 study. This may be one
of our study limitations. Tumor rebiopsy shall become a
norm before commencement of 2nd EGFR-TKI therapy
after failure to the first one especially when patients
were advised to join the clinical trials using T790M-spe-
cific TKI [38]. The relatively small sample size was an-
other limitation. In addition, comparison of afatinib with
erlotinib was not performed in a randomized-controlled
trial basis though data for the patients in the erlotinib
cohort were prospectively collected. It is difficult to be
carry out such randomized-controlled trial, however,
having realized the very limited efficacy of erlotinib after
prior failure to gefitinib shown in previous studies [26–30].
Notwithstanding, our study provided important clinical
information on the efficacy and safety of afatinib as 2nd
TKI therapy and its comparable anti-tumor activity but
with a different toxicity profile compared to erlotinib in
this setting.
Conclusion
Our study demonstrated the ability of afatinib to prolong
disease progression with similar survival outcomes but
different toxicities compared to those who received erlo-
tinib, and a comparable efficacy at least as comparable
as that shown in LUX-Lung1 study.
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